Novel Agents in Early Trials for Breast Cancer
Sara Hurvitz, MD1
, July 11, 2012
CancerNetwork speaks with Dr. Sara Hurvitz, director of the breast cancer program at the University of California in Los Angeles. Dr. Hurvitz is actively involved in translational phase I/II breast cancer clinical trials as well as in research to better define distinct types of breast tumors to better design novel targeted therapies.
Diagnosing and Treating Metastatic Pancreatic Cancer
Diane Simeone, MD1
, July 5, 2012
CancerNetwork discusses the diagnosis and treatment of metastatic pancreatic cancer with Dr. Diane Simeone, who is involved in both pancreatic cancer clinical trials as well as research to better characterize important pancreatic cancer pathways and identify biomarkers for the disease.
Breast Cancer at ASCO: Latest Trial Results and Emerging Therapies
Kimberly Blackwell, MD1
, June 21, 2012
CancerNetwork and the journal ONCOLOGY present an exclusive interview with Dr. Kimberly Blackwell, Duke Cancer Institute, who discusses some of the most important information to come out of this year’s meeting and talks about the future of breast cancer research.
ASCO: 'New, Exciting Era' for Research and Treatment of CLL
Hagop Kantarjian, MD1
, June 18, 2012
CancerNetwork speaks with Hagop Kantarjian, MD, M.D. Anderson Cancer Center, who shares his impressions of some of the highlights of this year’s ASCO meeting with regard to hematologic malignancies.
Melanoma at ASCO: Latest Treatments and Emerging Therapies
Michael B. Atkins, MD1
, June 11, 2012
In this exclusive interview, Michael B. Atkins, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses some of the most important melanoma research to come out of this year’s ASCO meeting and talks about the future of melanoma therapies.
Lung Cancer Screening Guidelines Updated
Harold Sox, MD1, Peter Bach, MD2
, May 25, 2012
The debate over screening for lung cancer continues. While there have been many advances in treatment for late-stage disease, screening and prevention are likely the most cost effective and best approaches to preventing lung cancer deaths.
New Approach Prevents Invasiveness of Ductal Carcinoma In Situ of the Breast
Interviewed by Anna Azvolinsky, PhD
, April 20, 2012
Ductal carcinoma in situ (DCIS) is the most commonly diagnosed, noninvasive type of breast cancer in women. In this interview Dr. Lance Liotta and Professor Virginia Espina, whose laboratory has been one the first to successfully culture living DCIS cells, discuss novel ways to stop breast cancer before it becomes invasive and malignant.
MBCC: Emerging Therapies for Triple-Negative Breast Cancer
Joyce O’Shaughnessy, MD1
, March 12, 2012
Triple-negative breast cancer is aggressive, has a high rate of metastases, and carries a poor prognosis. Dr. Joyce O’Shaughnessy, who will be presenting at the Miami Breast Cancer Conference, discusses an overview of new therapies for triple-negative breast cancer.
Advances in Colorectal Cancer Screening
David Ahlquist, MD1
, February 9, 2012
In this interview, Dr. David Ahlquist, gastroenterologist and professor of medicine at the Mayo Clinic in Rochester in Minnesota, discusses early detection methods of colorectal cancer, touching on sigmoidoscopy, colonoscopies, fecal blood testing, and in particular, stool DNA screening.
Advances and New Research in the Treatment of Kidney Cancer
Michael B. Atkins, MD1
, February 3, 2012
CancerNetwork speaks with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments, and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium.
SABCS: Kent Osborne Discusses Upcoming Research From This Year's Conference
Interviewed by Anna Azvolinsky
, December 2, 2011
CancerNetwork interviews Kent Osborne, who is the moderator of the year in review session. He has been involved with the meeting since its beginning. The international San Antonio Breast Cancer Symposium is unique as it facilitates the interaction of both basic and science researchers and clinicians to combine the efforts of laboratory research and clinical research for better treatment and patient care.
Joseph Sparano on Gene Expression Assays for Breast Cancer
Interviewed by Rachel Warren1
, August 30, 2011
CancerNetwork speaks with Dr. Joseph Sparano, professor of medicine and women’s health at the Albert Einstein School of Medicine and associate chairman of the department of oncology at Montefiore Medical Center in New York, about the session he will chair at the ASCO Breast Cancer Symposium on September 8-10, in San Francisco.
Student Innovation Holds Promise for Breast Cancer Screening
Interview Conducted by Sara Michael
, April 6, 2011
Imagine a faster, inexpensive method for breast cancer screening. That’s some of the promise behind a new innovation from doctoral student, Sevan Goenezen, who has discovered a way to use ultrasound and advanced algorithms to differentiate between benign and malignant tumors.
Biomarkers, Pathology Help Target Breast Cancer Treatment
, March 9, 2011
The combination of biomarkers and molecular pathology will aid oncologists in developing targeted treatments for breast cancer, according to Samuel Aparicio, MD, PhD, who will be delivering a presentation on recognizing breast cancer heterogeneity in targeted treatment at the Miami Breast Cancer Conference this week.
Next Generation Treatment for Triple-Negative and Basal-Cell Breast Cancer
, March 9, 2011
The early promise of treating triple-negative and basal-cell breast cancers with poly (ADP-ribose) polymerase (PARP) inhibitors is yet to be realized, according to Lisa A. Carey, MD, who will be delivering a presentation on treatment options for these patients at the Miami Breast Cancer Conference this week.
HER2-Positive Breast Cancer Demonstrates Heterogenous Outcomes
, March 8, 2011
The discovery of Human Epidermal growth factor Receptor 2 (HER2) positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.
Genomic Profiles: Not Yet Ready for Full Time Use
, March 8, 2011
Are genomic profiles refined enough that they should be used routinely to determine which breast cancer patients should receive adjuvant therapy? According to J. Michael Dixon, MD, who will be presenting the contra argument to this question in a debate at the Miami Breast Cancer Conference this week, the answer is: Not yet.
50 Shades of Pink—And Why It Helps to Know the Difference
Rebecca Bechhold, MD1
, May 17, 2013
Buy toxic chemicals and support breast cancer research! Not lying—just saw an ad on TV for weed killer and it had a pink ribbon logo on its packaging indicating, “A portion of every sale goes to support breast cancer research and awareness.” We have plenty of weed killer and a perfect lawn at our house, so I am no critic of the product. But have you noticed the pink ribbon logo on virtually every conceivable item or service?